Literature DB >> 26114491

Restoration of Outer Retinal Layers After Aflibercept Therapy in Exudative AMD: Prognostic Value.

Florence Coscas1, Gabriel Coscas1, Marco Lupidi2, Ali Dirani3, Mayer Srour4, Oudy Semoun4, Catherine Français5, Eric H Souied4.   

Abstract

PURPOSE: To evaluate the outer retinal layer (ellipsoid zone [EZ] and external limiting membrane [ELM]) changes following intravitreal aflibercept injections in eyes with treatment-naïve exudative age-related macular degeneration (eAMD) and to correlate these changes with fluid response and visual improvement.
METHODS: A retrospective case series of 50 treatment-naïve eAMD eyes followed-up for 18 months. All patients underwent regular comprehensive ophthalmic examinations. The presence of EZ disruption, ELM disruption, EZ swelling, subretinal hyper-reflective exudation (SHE), central macular thickness (CMT), cystoid spaces, subretinal fluid, and pigmented epithelium detachment were evaluated by two different retinal specialists at baseline and final visits, and correlated with best corrected visual acuity (BCVA) improvement.
RESULTS: At 18 months, BCVA, EZ disruption, ELM disruption, EZ swelling and SHE improved significantly (P = 0.001) at 18 months. Improvement of BCVA showed a statistically significant correlation with ELM restoration (P = 0.018), but not with EZ restoration (P = 0.581). Swelling of the EZ decreased from 72% of the cases at baseline to 30% in 18 months while SHE decreased from 52% to 6% in 18 months (P = 0.001). We observed a statistically significant (P = 0.001) reduction between the baseline and final value of CMT.
CONCLUSIONS: Aflibercept is safe and effective in treating exudative AMD with the restoration of the outer retinal layers. Restoration of the EZ is not statistically correlated with the final BCVA, even though persistent EZ changes could be associated with irreversible decrease in vision. On the contrary, the final status of the ELM is directly correlated with final BCVA. Also, baseline changes in outer retinal layers, especially the ELM, appear to predict photoreceptor restoration and final BCVA, and must be comprehensively analyzed to enable and determine a future prognosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26114491     DOI: 10.1167/iovs.15-16735

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  17 in total

1.  Choriocapillaris' alterations in the presence of reticular pseudodrusen compared to drusen: study based on OCTA findings.

Authors:  Irini Chatziralli; George Theodossiadis; Dimitrios Panagiotidis; Paraskevi Pousoulidi; Panagiotis Theodossiadis
Journal:  Int Ophthalmol       Date:  2017-08-04       Impact factor: 2.031

2.  Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.

Authors:  Nathalie Massamba; Ali Dirani; Nathalie Butel; Christine Fardeau; Bahram Bodaghi; April Ingram; Phuc Lehoang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-07-11       Impact factor: 3.117

3.  Quantification of retinal changes after resolution of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.

Authors:  Jae Hui Kim; Young Suk Chang; Dong Won Lee; Chul Gu Kim; Jong Woo Kim
Journal:  Jpn J Ophthalmol       Date:  2017-11-29       Impact factor: 2.447

4.  Quantitative analysis of photoreceptor layer reflectivity on en-face optical coherence tomography as an estimator of cone density.

Authors:  Maher Saleh; Mathieu Flores; Anne Sophie Gauthier; Emeric Elphege; Bernard Delbosc
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-08       Impact factor: 3.117

5.  Volumetric ellipsoid zone mapping for enhanced visualisation of outer retinal integrity with optical coherence tomography.

Authors:  Yuji Itoh; Amit Vasanji; Justis P Ehlers
Journal:  Br J Ophthalmol       Date:  2015-07-22       Impact factor: 4.638

6.  Long-term natural history of idiopathic epiretinal membranes with good visual acuity.

Authors:  Kieu-Yen Luu; Tynisha Koenigsaecker; Amirfarbod Yazdanyar; Lekha Mukkamala; Blythe P Durbin-Johnson; Lawrence S Morse; Ala Moshiri; Susanna S Park; Glenn Yiu
Journal:  Eye (Lond)       Date:  2019-04-19       Impact factor: 3.775

7.  Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.

Authors:  Glenn Yiu; R Joel Welch; Yinwen Wang; Zhe Wang; Pin-Wen Wang; Zdenka Haskova
Journal:  Ophthalmol Retina       Date:  2019-08-28

8.  Response to treatment with intravitreal anti-vascular endothelial growth factors in bilateral exudative cuticular drusen.

Authors:  Yusuf K Durlu
Journal:  Am J Ophthalmol Case Rep       Date:  2021-04-26

9.  Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series.

Authors:  Geraldine R Slean; Kornwipa Hemarat; Rahul N Khurana; Jay M Stewart
Journal:  Int J Retina Vitreous       Date:  2016-01-25

Review 10.  Baseline Predictors of Visual Acuity Outcome in Patients with Wet Age-Related Macular Degeneration.

Authors:  Xinyuan Zhang; Timothy Y Y Lai
Journal:  Biomed Res Int       Date:  2018-02-26       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.